glutathione synthetase Antibody (OTI1B8) (NBP2-03351): Novus Biologicals Human GSS (Glutathione Synthetase) knockout

Its natural to wonder: How do these peptide therapies compare to GLP-1 agonists like semaglutide (Ozempic) or tirzepatide (the dual agonist Mounjaro)

TB-500 is a research designation commonly used for thymosin beta-4related peptide sequences

Source: PubChem Structure of AOD-9604 Sequence: H-Tyr-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe-OH Molecular Formula: C78H123N23O23S2 Molecular Weight: 1815.1 g/mol PubChem CID: 71300630 What Are The Research Benefits of AOD-9604 Targeted Fat Reduction: Australia Scientific research suggests AOD may assist in fat burning by targeting localised fat deposits

The original paper is in Mandarin and you can access it here (paywall): #Type2Diabetes #DiabetesResearch #Obesity #GLP1 #Semaglutide #Dorzagliatin #MetabolicHealth #HuaMedicine To view or add a comment, sign in A newly published peer-reviewed scientific paper from China adds to the growing body of evidence around the benefits that dorzagliatin (GKA) in combination with the popular semaglutide (GLP-1RA) delivers superior glycemic control, weight reduction, and islet cell function improvement when compared with semaglutide monotherapy in obese patients with Type 2 diabetes mellitus (T2DM), with a comparable safety profile